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This newsletter was jointly developed and 
subject to editorial review by Jefferson 
School of Population Health and Lilly 
USA, LLC, and is supported through 
funding by Lilly USA, LLC. The content 
and viewpoints expressed are those of the 
individual authors, and are not necessarily 
those of Lilly USA, LLC or the Jefferson 
School of Population Health.
This issue marks 2 important transitions 
in the 6-year history of Prescriptions for 
Excellence. The first is that our 3-part series 
on health care organization governance 
has come to an end. Collectively, the 
articles in the series validate my initial 
editorial comment1 that “governance is 
risky business” and provide an up-to-date 
tutorial on this multidimensional topic. 
Judging from the feedback I’ve received, 
including requests for additional copies, 
many readers agree.
As those who know me can attest, I am 
a huge proponent of disseminating print 
material via hard copy. For me, referring 
someone to a Web site doesn’t have the 
same cachet as handing him or her a 
tangible item. So it is with mixed feelings 
that I announce the second transition. 
Beginning with the Fall 2013 issue, 
Prescriptions for Excellence will transition 
into a digital publication. Readers can rest 
assured that the timeliness, applicability, 
and quality of the content will continue 
at the same high level. 
Before wrapping up the topic of 
governance, I’d like to touch on an aspect 
that may be an uncomfortable topic 
for physician leaders — specifically, 
the governance risks associated with 
confidentiality, conflicts of interest, 
and related fiduciary issues. As hospital 
and health system boards respond to 
the Affordable Care Act’s (ACA) call 
for integrated strategies, boards must 
be particularly sensitive to these areas. 
Consider the following scenario: 
Acting in response to the ACA, a 
medical center’s governing board meets 
to formulate a plan for incorporating an 
accountable care organization (ACO) 
and a patient-centered medical home 
(PCMH). Sitting on the board are 6 
physician members of the center’s medical 
staff, 2 of whom have relationships with 
competing provider organizations (eg, 
imaging laboratory). One discloses the 
relationship and recuses herself from 
confidential discussions pertaining to 
the particular service. The other secretly 
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transmits confidential information to 
the competing organization, thereby 
undermining the medical center’s 
integration efforts. 
Although hypothetical, the scenario 
isn’t as far-fetched as it sounds. In fact, 
the authors who created it reported 
disturbingly similar events that had 
occurred, one of which led to a 1995 
California jury award of nearly $14 
million in damages to a hospital in a 
lawsuit against 2 former physicians who 
were alleged to have similarly exploited 
their governing board positions to build 
their own competing facilities and steer 
patients to them.2
Physician directors make vitally 
important governance contributions 
to health care organizations. However, 
when governing boards consider new 
proprietary strategic integration models, 
a physician director is in a potentially 
difficult position if discussions involve his 
or her medical practice and/or business. 
Boards that anticipate such risks 
and take a proactive approach can 
minimize the potentially adverse 
effects of such biases or other conflicts 
of interest. The authors suggest a 
formal plan that includes: general 
board education on applicable state 
law regarding the director’s duty of 
loyalty, targeted briefing of the board’s 
conflicts committee and of physician 
directors on the potential issues arising 
from consideration of integration-
based strategies, careful monitoring 
of board and committee agendas to 
identify sensitive discussion items in 
advance, making the hospital’s legal 
counsel available to physician directors 
for consultation on specific issues, 
and assisting the board’s conflicts 
committee to resolve disclosed 
potential issues (eg, adopting specific 
conflicts management plans). 
I’ll close with kudos to the authors 
in this issue who shared their keen 
insights into governance in 4 key areas: 
the continuing impact of the ACA on 
governance (“Governance Implications of 
the Affordable Care Act and Other Health 
Care Trends”), governance in large health 
systems (“Using Quality and Safety Data 
for Board Engagement That Makes a 
Difference in Patients’ Lives”), the impact 
of external forces on governance (“The 
Future of Governance: Health Care Boards 
Change with Challenging Times”), and an 
enlightening study of governing boards 
(“Board Size and Composition in Large 
Nonprofit Health Systems”) that reveals 
both how far we’ve come and how far 
we have yet to go. 
As always, I welcome feedback from 
our readers at david.nash@jefferson.edu.
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Among the insightful perspectives 
in this issue of Prescriptions for 
Excellence, perhaps none is more 
important than the need for 
governance boards to look forward 
— particularly as the hospitals and 
health systems they oversee drive 
significant shifts in our national 
health care landscape. In surveying 
the future, we must not lose sight of 
one of the vital drivers of improving 
long-term patient outcomes: the 
pursuit of medical innovation.
While much of this discussion lies 
at the federal policy level, much also 
rests in the hands of the growing 
number of state health insurance 
exchanges (HIE), integrated health 
systems, and accountable care 
organizations across the United 
States. Washington’s reforms may 
have accelerated the pace of change, 
but it will be up to individual systems 
— and, by nature, their governing 
boards — to bring them to life for the 
advancement of quality patient care.
As Barry Bader writes in an 
article that follows, “Success under 
the incentives of reform will be 
determined by how hospitals and 
health systems redesign care delivery 
in order to drive down spending and 
improve outcomes.” In doing so, 
we must not harm the health care 
ecosystem that has so crucially fostered 
innovation — and with it, improved 
outcomes — over the long term.
In my former role as Deputy 
Secretary of Health and Human 
A Message from Lilly
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Services, I often met with my 
counterparts in the health 
ministries of other countries, and 
I found my position unique. Like 
the others, I was responsible for 
the financing and delivery of health 
care. But my portfolio also included 
innovation — most notably, 
oversight of the National Institutes 
of Health and the Food and Drug 
Administration (FDA). 
Unlike my colleagues, I had to 
balance the goals of reducing costs 
and sustaining innovation. This 
broader perspective also helped 
me appreciate the potential for 
innovation to reduce costs, improve 
quality, and allay suffering. As we 
struggle with the challenges of 
health care, a narrow focus on costs 
to the exclusion of innovation would 
be self-defeating.
What we need is a different 
perspective on the value of medical 
innovation and an understanding  
of what it will take to increase  
that value in the years ahead to 
improve our collective “ROI” — 
Return on Innovation.
Medical innovation over the past 
century transformed the basic 
expectations of human life that 
had prevailed since the dawn of 
civilization. Tens of millions of 
death sentences were lifted, and 
once-dreaded diseases became 
manageable chronic conditions. 
Consider our progress against 2 
leading killers:
•  Coronary heart disease (CHD): 
The death rate from CHD in 
the United States has declined 
by about two thirds since it 
peaked in 1968.1 There were 1.7 
million more Americans alive 
last year who would have died at 
the 1960s’ rate.2
•  Cancer: The American Cancer 
Society states that, from 1991 
to 2009, the death rate for all 
cancers dropped 20%. That’s 1.2 
million people who did not die 
from cancer.3
The cumulative impact of the medical 
innovation of the past century is 
nothing short of mind-boggling. 
In 1900, the average American life 
expectancy was age 47, and in 2000, 
it was age 78 — an unprecedented 
increase of 66% in 1 century! 
The biopharmaceutical industry is a 
big reason we’ve gained these extra 
decades. An analysis by Columbia 
University Professor Frank 
Lichtenberg found that launches of 
new medicines accounted for 40% 
of the increase in life expectancy 
during the 1980s and 1990s alone.4 
We all know people in their 70s 
— and even 80s — who have left 
behind rocking chairs for sea kayaks 
and cross-country skis and, while 
we’re all frustrated with the rise 
in overall health care spending, a 
big chunk of it is due to the fact 
that these folks are now healthy 
enough to get knee replacements or 
coronary artery bypasses or cancer 
treatments and continue their active 
lifestyles, which sounds a lot better 
than the alternative to me.
But we must ask: As we reform our 
health care system, are we building 
a new foundation that will make the 
breakthroughs of tomorrow possible?
The pursuit of innovation in any field 
is a difficult, high-risk venture. If 
innovation is to take root and grow, 
it requires a combination of elements 
we describe as an “ecosystem.” The 
health of the ecosystem starts with 
open access to health care markets 
with market-based pricing. For 
example, we believe that doctors and 
patients must remain the ones to 
choose, in an informed way, from all 
available treatment alternatives.
My message is simple: A myopic 
focus on cost control impacts 
prices, prices affect investment, 
investment affects innovation, and 
innovation affects quality of health 
outcomes. Innovation and freedom 
of competition play a critical role 
in our health care economies, and 
misguided — albeit well-intentioned 
— government and institutional 
policies can greatly stunt its growth.
Without question, the tension 
between meeting rising costs 
and investing in innovations for 
tomorrow is one of the most 
intractable questions political 
leaders face. Consider the European 
experience. Often, in trying to 
strike this balance, European policy 
makers lean too much toward short-
term savings and succumb to the 
temptation to control expenditures 
through direct price controls, cuts in 
reimbursement rates, delayed market 
access, and other subtle and not-so-
subtle practices that either restrict 
the amounts paid for innovative 
products or reduce consumption of 
innovative medicines and devices.
Unfortunately, these trends have 
recently spread across the Atlantic 
and are rearing their heads in 
(continued on page 4)
4 Prescriptions for Excellence in Health Care
This newsletter was jointly developed and subject to editorial review by Jefferson School of Population Health and Lilly USA, LLC, and is supported through funding by Lilly USA, LLC. 
our commercial and government 
systems here in the United States 
with disturbing frequency.
Why does this matter? Because 
there is a direct relationship between 
these types of cost containment 
measures and innovation. A study 
by the US Commerce Department 
evaluated cost controls in a number 
of industrialized countries and 
found that lifting cost controls 
could increase revenues for patented 
medicines by as much as $18 
billion to $27 billion annually — 
something that would greatly foster 
innovation.5 This translates into as 
much as $5-$8 billion of lost global 
research and development as a result 
of cost controls.
Rather than looking at cost as 
the only driver of value, we must 
implement market-based solutions 
to sustain innovation in the future. 
Consumers are served best by 
free, strong competition that 
creates choices, better prices, and 
broader benefits while encouraging 
sustainable innovation.
Contrast the European experience 
with our own great American 
experiment with Medicare Part D 
— the only part of our government-
sponsored health care system that 
does not have the distortion of price 
controls. Part D has been a bigger 
win than even those of us who 
helped launch it imagined. Costs 
have been 40% below the original 
Congressional Budget Office 
estimate, and beneficiaries report a 
90% satisfaction rate.6
As HIEs resulting from the 
Affordable Care Act launch later  
this year, we should be looking 
to Part D for learnings to foster 
maximum competition. When you 
have a competitive health insurance 
market, with a well-informed 
beneficiary in the driver’s seat making 
choices rather than bureaucrats, 
the value of the medicine — and 
innovation — is preserved.
If the sole impact of biopharmaceutical 
innovation was additional decades 
of life and health, we’d be hard-
pressed to find its equal. There’s also 
compelling evidence that innovative 
medicines are the most cost-effective 
part of health care. A couple years 
ago, former Medco CEO David 
Snow visited Lilly and reported 
that it costs half as much to treat 
patients with diabetes who adhered 
to their prescribed course of medicine 
compared to those who didn’t.
Medicines are not cost drivers, they’re 
cost savers. In 2011, the Journal of the 
American Medical Association reported 
that when seniors who didn’t have 
comprehensive prescription drug 
coverage received coverage through 
Medicare Part D, they saved an 
average of $1200 per year in hospital, 
nursing home, and other medical 
costs.7 That translates into $12 billion 
per year in savings across Medicare.8 
David Snow summed it up well: 
“Drugs used properly are part of the 
solution, not part of the problem.”
Some people will still say that we 
have all the innovation we need 
or that, in this difficult economic 
climate, we just can’t afford it. But 
we must build upon — not rest 
upon — the contributions of the 
past. For all our tremendous progress, 
much more remains to be done.
With 10,000 American baby 
boomers turning 65 every day, it’s 
not surprising that we’re seeing a 
sharp increase in the incidence of 
diseases associated with aging (eg, 
cancer, type 2 diabetes, osteoporosis, 
neurodegenerative diseases). The 
Alzheimer’s Association estimates 
that by 2050 — absent effective 
treatments — the number of 
Americans over age 65 who develop 
Alzheimer’s will triple to 13.8 
million, and costs in the United 
States alone could rise to $1.2 
trillion a year.9
Let’s face it: The only way to 
make further inroads against these 
and other conditions is to sustain 
medical innovation. The good news 
is that advances in the life sciences 
are bringing treatments, once 
beyond our reach, finally into view. 
One need look no further than the 
35 new molecular entities approved 
by FDA in 2012. 
But we can’t stop the revolution 
cold in its steps as our health care 
system continues down the path 
of rapid reform. Clearly, when it 
comes to sustaining innovation, the 
burden remains on research-based 
companies like Lilly — as it should. 
Businesses that live or die by health 
care innovation ask only that we be 
allowed to continue doing just that: 
Proving the value of what we’ve 
developed … and succeeding or 
failing in the marketplace.
It is impossible to predict the 
full range of benefits that future 
generations could enjoy from today’s 
innovation, but when I think of the 
incredible advances in medicine 
over the past century, I’m convinced 
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that what might seem unimaginable 
today will be commonplace 
tomorrow. For example: 
•  treatments that transform cancer 
into a chronic disease, with 
survival times measured in decades 
rather than months,
•  effective treatments for malaria, 
tuberculosis, and other diseases 
affecting tens of millions in the 
developing world,
•  breakthroughs that will save 
millions from the devastation of 
Alzheimer’s disease,
•  cardiovascular repair and 
prevention of heart disease,
•  replacement organs, and, 
ultimately,
•  additional healthy, productive 
years for people to enjoy life with 
enhanced vitality. 
As members of health care governance 
boards grapple with cost and quality 
questions, I hope they too will 
conclude that innovation is not the 
problem. Innovation is the solution — 
the essential key to ensuring that our 
ecosystem remains healthy and viable 
to deliver improved patient outcomes 
for years to come.
Alex M. Azar II is the President of Lilly 
USA, LLC, the U.S. affiliate of Eli Lilly 
and Company, and is a former Deputy 
Secretary of Health and Human Services. 
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As much as hospitals and health systems 
have grown and changed over the past 
several decades, their governance has 
tended to retain many traits from their 
roots. These often include recruiting 
trustees from the local community’s 
business and finance elite, limiting what 
is expected from volunteers, measuring 
performance mainly in the acute care 
setting, and allocating “representation” to 
a semiautonomous medical staff. 
In recent years, however, several powerful 
forces have necessitated significant 
changes in the governance of not-for-
profit hospitals and health systems:
•  Higher expectations for corporate 
accountability and director 
professionalism are requiring 
boards to be more accountable, 
independent, and transparent, and 
to follow “best practices” such as 
competency-based selection to 
optimize their effectiveness. 
•  Recognition that, in this era of 
industry aggregation (ie, spread 
of multihospital systems, and 
increasing economic alignment of 
hospitals and physicians), boards 
are governing large, complex, 
diversified organizations that require 
optimization of system-wide rather 
than silo performance to be successful.
•  Heightened scrutiny of tax exempt 
organizations by Congress, the 
Internal Revenue Service (IRS), 
state governments, and the courts 
means not-for-profit boards can 
no longer take their tax status for 
Governance Implications of the Affordable Care Act and Other Health Care Trends
By Barry S. Bader
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granted. They must be prepared to 
demonstrate their organizations’ 
community benefit, responsible 
stewardship, and ethical conduct to 
“earn” their tax breaks. 
Looking ahead, the reduced 
reimbursements, value-based payment 
methods and quality incentives 
embodied in the Affordable Care 
Act and embraced by private payers 
are expected to drive further industry 
aggregation and performance 
improvement. Success under the 
incentives of reform will be determined 
by how hospitals and health systems 
redesign care delivery in order to drive 
down spending and improve outcomes. 
These organizations must transform 
into high-performing, integrated 
delivery systems that are accountable 
for their costs and quality across the 
full continuum of care. 
Three Structural Models of Future Care 
System Governance
Each hospital and health system must 
undertake a candid self-examination of 
its governance. Are there certain hospital-
rooted roles, structures, and practices 
that once were strengths but that could 
be impediments to high-performing 
care system governance? Are current 
structures and practices sufficiently 
robust to evolve as the delivery system 
transforms or does the governance model 
require a complete overhaul? 
It may be useful for boards to think 
about 3 emerging governance models, 
described in a recent survey of health 
system leaders by the American Society 
for Healthcare Strategic Planning and 
Marketing and the American College 
of Healthcare Executives. The models 
reflect different core properties of 
various care systems (Figure 1). 
Professional Governance Model: 
Organizations that see themselves as 
a “health company” (ie, not-for-profit 
in motive but possessing the culture of 
a customer-focused, high-performing 
corporate enterprise) may adopt this 
model wherein governance is viewed 
as a “professional commitment” of 
the highest order by hard-working 
directors as in the best corporate 
boards. Whether compensated or 
not, such boards impose higher 
expectations on directors’ performance 
than the typical volunteer board. 
Directors are recruited wherever 
the best talent resides — locally or 
outside the communities served. Board 
composition is based on exceptional 
competence in needed skills and 
independence (ie, no material conflicts 
of interest). 
Organizationally, such boards have 
a lean approach to size, committee 
structure, and meeting frequency — 
all intended to drive a collaborative 
team culture of high-performing, 
independent, and accountable 
governance. A single parent board 
has unquestioned authority; local 
subsidiary boards, if retained, serve 
in advisory roles although large, 
multistate care systems may retain 
regional governing bodies with 
delegated authority and responsibility. 
Clinical Enterprise Governance: This 
model is designed for organizations that 
view themselves as primarily clinical 
enterprises that are physician-driven, 
professionally managed, and patient-
centered. Medical and professional 
staff are employed or under contract, 
and clinical services are comanaged by 
“dyads” of physician and nonphysician 
leaders such as nurse executives. 
Governance often involves 2 boards that 
have clearly delineated authority and 
roles. A corporate parent or foundation 
board has ultimate decision-making 
authority and focuses on high-level 
strategy, goal setting, and independent 
oversight. An empowered and active 
clinical enterprise board of senior 
executives and senior physician and 
nursing leaders is the engine for 
delivery system leadership that is fully 
accountable to the parent board for 
the patient experience, clinical quality, 
financial results, and clinical operations. 
In addition to the chief executive  
officer (CEO) and chief medical  
officer, the parent board includes 
predominantly, or all, independent 
directors. As in the Professional 
Governance Model, local and outside 
parent board directors are selected 
mainly on the basis of needed 
competencies. 
Enhanced, Community-based 
Governance: Organizations that see 
themselves primarily as integrally 
connected to and serving mainly their 
local communities retain a community 
flavor in their board composition and 
its scope of work; however, they tend 
to adopt sensible enhancements to 
assure director professionalism and 
to facilitate transformation to an 
accountable care system. 
This model likely has a parent board 
with broad-based composition 
Figure 1. Three Emerging Care System 
Governance Models
Source: American Society for Healthcare Strategic Planning and 
Marketing and the American College of Healthcare Executives.
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drawn from the communities served. 
Competency-based succession planning 
for the board is more rigorous and 
ongoing than it is on most boards 
today, but most trustees still come from 
the community served. Diversity is a 
higher priority, and at least a majority 
of board members meet the IRS 
independence test. The board may 
include several staff physicians who are 
selected using the same competency-
based criteria and selection process as  
any other trustee rather than as medical 
staff representatives. 
An active working committee structure 
engages trustees and other leaders; 
committees do the heavy lifting for 
the board’s core responsibilities (eg, 
finance, audit, compliance, quality, 
community benefit, governance). 
Subsidiary boards may be eliminated or 
retained in advisory and/or community 
connectedness roles. 
As each board envisions its ideal 
governance model for the future, it 
is likely to adopt a hybrid of the 3 
prototypes, drawing relevant attributes 
from each model to construct 
its desired “board of the future.” 
Professional boards, for example, 
select trustees based on particular 
competencies but still may look to 
their service areas for trustees with 
connections or philanthropic ability. 
Like professional boards, community-
based boards will expect more from 
their trustees and focus more time on 
strategy, and clinical enterprise boards 
will draw elements from both models. 
Best Practices Will Be Widely Adopted
Structural reform alone is not enough. 
The literature on effective governance 
has grown exponentially in recent years. 
As evidence mounts regarding which 
practices are truly connected with 
better performance for the organization 
and board, boards must move from 
viewing best practices as aspirational 
to making them standard governance 
procedure. Some practices are 
particularly important to care system 
transformation and will apply across 
multiple models of future governance. 
These include:
•  CEO support: Recognizing that a 
CEO who wants an informed and 
engaged board and actively supports 
its work is essential to high-
performing governance, boards will 
explicitly select and evaluate CEOs 
for this attribute.
•  Expert competency: Board 
composition will include at least 
1 independent expert in each of 
the board’s core responsibilities; 
notably, finance, quality, executive 
leadership, and audit. Boards also 
will include new backgrounds 
and skills consistent with being 
an accountable care system (eg, 
expert knowledge and leadership 
experience in population health 
and enterprise risk management). 
Lacking sufficient expertise locally, 
smaller community boards may 
need to broaden their outreach. 
•  Quality: Boards will elevate 
quality to strategic priority status 
that requires planning as well as 
oversight. They will expand their 
purview to embrace the Triple Aim: 
improving the patient experience, 
the per capita cost of care, and 
the health of communities or 
populations. They will adopt the 
board practices that evidence 
indicates are connected with 
higher performance by the board, 
the organization, or both. These 
include spending at least 20% of the 
board meeting time substantively 
discussing quality performance, 
using a board quality subcommittee 
to perform more in-depth oversight 
than the full board can, reviewing 
a dashboard of quality indicators 
regularly, setting quality objectives 
for the CEO’s performance 
evaluation, and participating with 
medical staff leaders in establishing 
quality and patient safety goals.1-3 
•  Transformational leadership: Boards 
will draw on a range of leadership 
tools that are suited to leading change 
and transforming organizations in 
an uncertain economic environment. 
These include: 
–  devoting 75% or more of board 
meeting times to substantive 
interaction on strategic issues rather 
than passively listening to reports 
–  embracing “generative governance 
concepts” to identify and explore 
questions that unearth new thinking 
in board discussions4
–  adopting scenario-based and “what 
if ” strategic planning methods 
–  employing bifocal metrics, focusing 
on 2 sets of metrics simultaneously: 
(1) keeping tabs on current 
performance, and (2) tracking 
progress toward long-term goals
–  using enterprise risk management 
techniques to assess the many types 
of risk that exist in a changing 
environment (ie, financial, strategic, 
regulatory, reputational).
•  Community benefit: As a matter 
of both mission and economics, 
boards will devote increased 
attention to community benefit, 
community health improvement, 
and elimination of health 
disparities as strategic priorities.
•  Capacity for collaboration: Boards 
must strengthen their capacity 
(continued on page 8)
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for trust and collaboration as 
care systems pursue their aims in 
cooperation with organizations 
outside of their control (eg, 
accountable care organizations, 
medical homes, public health 
agencies, private insurance plans.) 
•  Board self-evaluation: Boards 
will link board evaluation with 
specific board improvement plans. 
They also will adopt an individual 
director assessment process to 
reinforce performance expectations 
by providing directors with 
constructive feedback and by  
using evaluations to make 
reelection decisions. 
Capacity for Self-Assessment  
and Improvement 
Boards that have established a culture 
characterized by accountability, trust, 
collaboration, candor, engagement, 
continuous learning, and self-
assessment will be well equipped to 
consider their need to enhance or 
overhaul their structure and practices. 
For boards that have not reached this 
point, the journey to a new governance 
model will be more challenging. 
Barry S. Bader is President of Bader 
& Associates, Healthcare Governance 
Consulting.  He can be reached at:  
barry@baderassociates.com. 
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Currently the largest health system and 
the fourth largest employer in Ohio, 
Catholic Health Partners (CHP) is one 
of the largest nonprofit health systems 
in the United States, with more than 
100 provider organizations that meet 
the health care needs of people in 
Ohio, Kentucky, and contiguous states. 
Operating under a decentralized 
model, CHP’s approach to governance 
and management balances decisions 
made at the local level with those 
made at the combined system level. 
Although each of CHP’s 7 regional 
health systems has its own board of 
trustees, all are ultimately accountable 
to the CHP board of trustees.
In 1999, CHP was part of a small but 
growing number of health systems that 
recognized the need to elevate quality 
to the same level of governance as other 
aspects of health system operations.1 
CHP’s board of trustees decided to 
create a board quality and patient 
safety (QPS) committee 5 years before 
the National Quality Forum (NQF) 
published Hospital Governing Boards and 
Quality of Care: A Call to Responsibility, 
encouraging hospital governing boards 
to become actively engaged in quality 
improvement and focusing attention 
on the relationship between governance 
and quality of care.2 
Though CHP was an early adopter of 
health care governance, initially QPS 
committee meetings dealt primarily 
with performance improvement project 
updates, crude performance dashboard 
reviews, and issues such as Joint 
Commission readiness. It was not until 
2002 that quality objectives were added 
to the system-wide annual plan. 
Today, all members of the CHP 
executive management team,  
including regional chief executive 
officers (CEOs) for the hospital 
system, are held accountable for 
meeting the quality performance goals 
of the annual plan. In retrospect, 
“top quartile” targets such as use 
of angiotensin-converting enzyme 
inhibitors for heart failure patients and 
timely use of antibiotics for pneumonia 
patients started CHP on a journey 
toward elevating the importance of 
QPS for the organization’s largely 
nonclinical administrative leadership.
Quality Measurement
After becoming a member of the NQF 
in 2002, CHP made a policy decision 
to use measures endorsed through 
NQF’s consensus development process 
whenever possible. In addition, 
the system formally embraced the 
Institute of Medicine’s Quality Chasm 
report as its framework for quality 
improvement,3 linking objectives and 
associated measures to the report’s 
6 aims. Consistent with the work of 
Berwick et al,4 CHP embedded a clear 
distinction between “measurement for 
accountability” and “measurement for 
process improvement” in its board-
approved policy on quality reporting 
and oversight. CHP adopted NQF’s 
Safe Practices5 at about the same time.
Using Quality and Safety Data for Board Engagement That Makes a Difference in 
Patients’ Lives
By Stephen R. Grossbart, PhD
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Measurement System
Originally, CHP’s decentralized model 
did not provide corporate staff with direct 
access to quality data. This changed 
with the gradual implementation of a 
system-wide decision-support system, 
computerized physician order entry, 
and an electronic health record at all 
ambulatory and hospital sites. This 
centralized information system is 
critical to providing timely information 
to the board and giving staff the data 
analytic ability to understand variances. 
Today, the board views information that 
typically is harvested through the month 
prior to meeting.
Executive Accountability
CHP has set incrementally higher 
expectations for its senior team to meet 
QPS objectives. In 2002, only 10% of 
the total number of system objectives 
focused on quality and safety. Today, over 
half of the system goals are directly tied 
to QPS. Each objective has equal weight 
in determining executive compensation. 
The board also requires the system to 
meet 3 threshold targets in the areas 
of finance, community benefit, and 
quality. Today, hospitals must meet a 
minimum performance threshold for 
patient experience to be eligible for any 
incentive compensation. Seven of CHP’s 
22 hospitals did not meet this target in 
2012 and their leadership teams did not 
receive bonuses. 
The board QPS committee regularly 
reviews data to ensure that performance 
levels meet minimum expectations and 
patients are not at risk of imminent 
harm. If data analysis reveals an issue or 
if significant patient events occur, the 
QPS committee may place any hospital 
or entity on “oversight,” an action that 
requires the regional CEO to attend 
a QPS committee meeting to outline 
an action plan to achieve minimum 
performance levels or eliminate the risk 
of patient harm. In addition, the regional 
board of trustees is updated on the reasons 
for the oversight. Three hospitals have 
been placed under the oversight of the 
CHP board QPS committee since 2009.
Boards on Board Campaign
A significant change for CHP came 
about as a result of the Institute for 
Healthcare Improvement’s (IHI) 5 
Million Lives Campaign, at which time 
CHP embraced the IHI’s Boards on 
Board campaign (ie, began to provide 
educational sessions to members of the 
system board of trustees and regional 
boards, and encouraged all regional boards 
to adopt the campaign planks). 6, 7
The IHI campaign called upon boards 
to understand 6 key steps to improving 
governance: (1) setting aims, (2) getting 
data and hearing stories, (3) establishing 
and monitoring system-level measures, 
(4) changing the environment, policies, 
and culture, (5) learning…starting with 
the board, and (6) establishing executive 
accountability. At that time, the board 
QPS committee had already set aims, 
established a monitoring system, and 
held senior system leaders accountable 
for quality performance, though many 
in the organization still believed finance 
trumped quality. In response to IHI’s 
emphasis on the need for culture 
change, the committee’s priorities 
shifted toward stories of patient harm 
and changing the environment, policies, 
and culture of the organization. 
CHP’s culture transformation began 
with tracking and reporting the rate of 
serious reportable events (SREs) based 
on the NQF definition.8 Hospital 
presidents were trained to make patient 
safety walk rounds, and the system 
CEO began to join individual hospital 
presidents on their walk rounds. The 
system adopted “just culture” principles 
and conducted its first Agency for 
Healthcare Research and Quality 
Patient Safety Culture Survey in 2005. 
A dramatic step toward changing culture 
was storytelling around tragic events 
involving patient harm. After hearing a 
story of patient harm at its April 2008 
meeting, storytelling by a regional CEO 
or hospital president became a required 
agenda item at virtually every board 
QPS committee meeting. 
Presentation of Data and Information
CHP has developed increasingly 
sophisticated mechanisms for sharing 
information with its board and 
QPS committee at multiple levels. 
Reviewed at every meeting, a high-
level dashboard identifies performance 
at system, regional, and facility levels, 
and provides information on multiple 
goals. For 2012, the dashboard tracked 
year-to-date performance on system-
level goals: (1) eliminate preventable 
harm, (2) reduce mortality, (3) improve 
patient experience, (4) reduce length 
of stay, (5) reduce readmissions, (6) 
improve emergency department 
median admit time, (7) patient-
centered medical home recognition, 
and (8) achieve CMS Partnerships 
for Patients goal to reduce hospital-
acquired conditions.
The board QPS committee also is 
provided with a detailed drill down 
on each goal as well as a control chart 
(Figure 1). Eliminating preventable 
harm has been a system objective since 
2010. Of the 5 harm measures tracked 
by CHP, reducing hospital-acquired 
falls and trauma with harm has proven 
most difficult to achieve. Quantitative 
data can be presented in many ways, 
enabling clinical staff to inform the 
QPS committee that:
•  CHP’s rate of patient falls with 
injury, an NQF SRE, has decreased 
(continued on page 10)
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2.5-fold since 2008, from a rate of 
0.637 falls per 1000 to 0.261 falls 
per 1000. 
•  This is substantially below the 
national average of 0.564 falls 
per 1000 reported in the CMS 
Hospital Compare database.
•  Fall rates have dropped below the 
historical average for 9 consecutive 
months beginning in September 
2011, representing a statistically 
significant improvement. 
One might ask, does the board need to 
know anything else about falls or should 
the staff be congratulated? If the staff was 
content, they would be failing to fully 
inform the board. In addition to reporting 
rates of falls, CHP shares the number of 
injuries that occur in our hospitals: 
•  Falls are an NQF SRE defined as 
“largely, if not entirely, preventable 
and serious.”
•  In 2008, a total of 104 patients 
fell and injured themselves in our 
hospitals, an average of 9 patients  
a month.
•  If trends during the first 8 months of 
2012 hold, then 53 patients will suffer 
a fall with injury, about 4.4 per month.
•  Over 25% of the hospitals in the 
United States report no falls.
•  Nine of CHP’s 22 acute care 
facilities have had zero falls 
through August 2012.
•  Evidence-based practices have been 
shown to reduce or eliminate the 
risk of falls; not all our hospitals 
adhere to these practices.
This additional information helps the 
board place what initially appears to be 
robust performance in the appropriate 
context. To put a human face on these 
data, CHP developed a quarterly “Failures 
of Care” report that highlights the impact 
of harm at a human level (Figure 2). 
System-wide Adoption of Best Practices
In 2012, CHP corporate QPS staff 
requested that each region share its 
Failures of Care report with local boards 
of trustees. Noting that best practices 
adopted at the system level had not 
been adopted consistently among the 
regional boards, the system’s executive 
management team requested that all 
regional CEOs begin to share stories 
consistently as outlined in the Boards on 
Board campaign and to share the Failures 
of Care report quarterly. 
Inconsistency in adoption of best 
practices across a system is not unique. As 
demonstrated by Jha and Epstein, “fewer 
than half of the boards rated quality 
of care as one of their 2 top priorities, 
and only a minority reported receiving 
training in quality.”9 This is little changed 
from Joshi and Hines’ finding in 2006.10
Conclusion
Six years since the launch of the Boards 
on Board campaign, many hospitals 
have yet to implement the necessary 
2009 - 139 Serious 
Reportable Events
2010 - 120 Serious 
Reportable Events
2011 - 100 Serious 
Reportable Events 
Eliminate 
Preventable Harm
2012 - 18 Serious Reportable 
Events - as of  3/31/2012
Sexual Assault 
Eugene - 28 year old Male
Surgery performed on 
wrong body part
Ada - 15 year old Female
Medication Error
Benjamin- 54 year old Male
Precious - 82 year old Female
Retained Foreign Object
Max - 67 year old Male
Rita - 26 year old Female
Fall
Jill - 33 year old Female
Mary - 76 year old Female
Hannah - 82 year old Female
Curtis - 85 year old Male
Lynn- 89 year old Female
Henry - 82 year old Male
John - 83 year old Male
Anne - 82 year old Female
Dorthy - 73 year old Female
Sharon - 60 year old Female
Katerine - 65 year old Female
Joan - 92 year old Female
Figure 2. Failures of Care Report
Figure 1. Proportion of Patients with Falls or Trauma
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(continued on page 12)
cultural changes, measurement systems, 
and governance changes to achieve the 
goals of the 5 Million Lives Campaign. 
Ultimately, the ability of staff to support 
good governance depends primarily 
on the senior team’s commitment 
to leadership practices focused on 
providing data and information with a 
high level of transparency. 11,12
Stephen R. Grossbart, PhD, is Senior Vice 
President and Chief Quality Officer at 
Catholic Health Partners. He can be reached 
at: srgrossbart@health-partners.org.
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Health care is arguably the most rapidly 
changing industry in America. These 
are turbulent times for boards and chief 
executive officers (CEOs) who face 
difficult issues and mounting uncertainty. 
Unless the health care enterprise is a 
sustainable business model, even the best 
governance cannot assure success. The 
crucial question facing boards today is 
whether the health care enterprise can 
transform itself fast enough to succeed in 
the face of all this turbulence. 
In preparing for this article, 25 
health care industry leaders with over 
1000 years of collective governance 
experience were interviewed. Ten 
themes emerged from these interviews.
1.  Health care boards will continue to 
become smaller 
An important change in governance of 
nonprofit hospitals and health systems 
will be in the size of boards. According 
to the American Hospital Association, 
most boards today have between 15 and 
18 board members, and some of the 
largest ones have 30 or more directors. 
Many of these boards are still too big to 
assure effective governance. 
 
Smaller boards lead to a 
greater sense of ownership and 
accountability. Members come to 
meetings better prepared and feel 
more satisfaction in their board 
service. Smaller boards are less 
cumbersome decision makers and 
take action more promptly when it  
is needed. 
2.  Boards will govern larger and more 
complex clinical enterprises 
Consolidation in the industry will 
continue to accelerate for one simple 
reason: scale matters. In addition 
to economic pressures, there are 
other compelling forces requiring 
hospitals and health systems to 
manage the entire continuum of 
care. The visionary health care 
enterprise is already focusing on 
managing the health of entire 
defined populations. 
We are witnessing a transformation 
in the way health care is delivered 
in this country, one that is driven by 
the simple reality that health care 
costs are growing at a rate that is 
unsustainable. This transformation 
will be a catalyst that ultimately 
requires boards to significantly 
upgrade their own performance.
3.  Boards will need to understand and 
manage risk 
With the growing complexity of health 
care systems comes increased risk in 
several areas — strategic, operational, 
financial, and compliance. In addition 
to regulatory risk more risk will arise 
from the growth and complexity of the 
enterprise, the challenge of physician-
hospital integration, quality issues, 
the expanded use of electronic health 
records while meeting Health Insurance 
Portability and Accountability Act 
privacy and security requirements, 
increasing reliance on outsourcing, 
and other factors. Environmental, 
economic, political, regulatory, and 
The Future of Governance: Health Care Boards Change with Challenging Times 
By F. Kenneth Ackerman, FACHE, FACMPE
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social landscapes are in a state of flux. At 
any given moment an unexpected crisis 
can demand an immediate response. 
 
The responsibility for risk oversight 
lies with the full board of directors. 
Boards will need to develop a clear 
understanding of the risks they face 
and avoid, mitigate, or monitor them. 
Risk scenario planning will become 
commonplace on good boards.  
 
Because many risks can be “value 
killers,” or “reputation killers,” they 
require constant vigilance. Board 
members must continually ask 
themselves, “What don’t we know that 
we should know?”
4.  Board composition will change 
Hospitals and health systems will 
focus more on the clinical enterprise, 
becoming obsessed with outcomes, 
quality, and safety. More of these 
organizations will be led by physician 
CEOs. Good governance requires 
independent directors with the right 
skill sets and expertise to make difficult 
decisions. More boards will look outside 
their communities to find directors 
with the requisite backgrounds, 
including industry experts (eg, physician 
executives, nurse executives, marketing 
executives, chief information officers, 
health insurance executives).  
 
The right board composition for any 
organization is driven by the vision and 
strategy of the enterprise. 
5.  Boards will become more diverse 
It is important to have a mix of 
perspectives on any issue. Racial, gender, 
and ethnic diversity helps to assure 
robust boardroom discussions when 
dealing with the strategic imperatives 
of the enterprise. If diversity doesn’t 
start with the board, it is often difficult 
to assure adequate diversity throughout 
the organization. However, finding 
directors with the appropriate skills and 
experience will remain the top priority.
6.  Boards will become more transparent 
Outside pressures, including the 
new Internal Revenue Service form 
990 and its schedule H, state and 
federal governments, and aggressive 
states’ attorneys general — all in 
an environment with Internet 
and 24/7 media attention — will 
drive organizations toward greater 
transparency. The public demand for 
higher quality, safety, and customer 
service create a need to demonstrate 
the “value proposition” for community 
wellness, disease prevention, better 
health outcomes, and lower costs. Also, 
transparency builds trust both inside and 
outside the organization.
7.  CEO succession will become a priority 
Despite the fact that CEO turnover has 
remained alarmingly high for the past 
decade, fewer than 20% of boards have a 
good succession plan in place. The lack 
of a formal succession plan heightens 
the possibility that the organization will 
need to recruit the next CEO from the 
outside, an option fraught with risk of a 
costly failure. 
 
Succession planning is a fundamental 
responsibility of the board. Successful 
transitions require careful planning by 
the board and the CEO. 
8.  Best practices will become the norm 
The current health care environment — 
with changing regulations, pressure from 
ratings agencies and payers, liability 
risks, rising public expectations, and the 
potential for public embarrassment if 
something goes wrong — is best dealt 
with by adhering to best practices.  
 
Sophisticated boards will constantly 
measure everything, including their own 
performance. They will conduct annual 
CEO appraisals, annual appraisals of 
board and committee chairs, reviews of 
board and committee performance, and 
peer- and self-evaluations of directors. 
Intentional self-examination over a 
sustained period will help improve 
board performance.
9.  Highly qualified directors will be difficult 
to find 
Board work today requires significantly 
more time than it did 10 years ago. 
Although there are rewards for board 
service there are drawbacks as well, 
including the rigors and risks of board 
membership, the travel and preparation 
time required, and concerns about 
personal liability and reputational risk. 
Other factors (eg, retirement of baby 
boomers, scarcity of CEOs willing 
and able to sit on outside boards ) are 
reducing the pool of candidates for 
board membership. 
 
The best boards are already thinking 
outside the box, expanding their search 
parameters, and looking outside their 
own communities to find well-qualified 
candidates to fill board positions. The 
use of professional search firms to 
identify qualified board members will 
become common practice. 
10.  More large health system boards will 
compensate directors 
The importance of finding the right 
candidate, an acknowledgement of 
the time requirements placed on 
board members, and the growing 
recognition that highly-qualified 
candidates have many opportunities 
to serve on other boards are among 
the primary reasons why many 
large health systems will consider 
compensating board members. 
 
Although director compensation 
is controversial, real value lies in 
the social contract that such pay 
establishes between the board and 
the organization. Boards must 
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A recent study examined board 
structures, processes, and cultures in a set 
of the country’s largest nonprofit systems 
and compared them to benchmarks of 
effective governance.1 The 4 phases of 
the methodology employed to gather 
and analyze information have been 
published previously.2 
Summary of Findings Regarding Board 
Size and Composition
Board Size 
Neither in the health care field nor 
other sectors is there an exact answer to 
the question, “How large should  
a board of directors be?” The 2007 
report of the Center for Healthcare 
Governance Blue Ribbon Panel on 
Healthcare Governance advocated a 
range of 9 to 17 voting members for 
hospital and health system boards.3 
Several other authorities have offered 
similar recommendations.
For 10 of the 14 systems, board size is 
consistent with the Blue Ribbon Panel’s 
recommendation. Three boards have 
between 18 and 28 voting members; 
1 board has 60 members. The median 
size is 15 members, excluding the 
outlier with 60 voting members.
The boards of these systems are somewhat 
larger than the boards of our country’s 
hospitals and health systems as a whole 
(whose average size consistently has been 
between 12 and 14 since 2005) and the 
boards of our country’s public companies 
(whose average size has remained in the 8 
to 9 range for many years).1
Board Composition 
Independence. The Sarbanes-Oxley 
Act of 2002 made the definition 
Board Size and Composition in Large Nonprofit Health Systems
By Lawrence Prybil, PhD, LFACHE
(continued on page 14)
weigh the decision to compensate 
directors carefully to determine 
whether it is the right decision for 
their particular situation. 
Summary 
The next 10 years will be a difficult 
time to serve on the board of a health 
care provider organization. Boards will 
need wisdom and courage to keep their 
organizations on the right course. They 
will need to follow governance best 
practices to demonstrate to a wary public 
that they are acting in the best interests 
of the patients and the communities 
they serve. They will need to deal 
with issues such as CEO turnover, 
physician integration, revenue and 
capital constraints, quality and safety 
issues, and mounting risks in governing 
bigger and more complicated enterprises 
— all in the face of changes in the 
environmental, economic, political, 
regulatory, and social landscapes. 
To meet the challenges of the future, 
boards must begin to operate differently 
than they did in the past by adopting 
best practices, recruiting directors 
carefully, being proactive and transparent, 
and making decisions quickly. Good 
governance will be essential to assure a 
high-performing health care enterprise 
in these challenging times. 
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of “independence” more stringent 
and increased the requirements for 
independent board members on the 
boards of public companies. The 
impact on the composition of public 
company boards has been striking. The 
proportion of independent directors on 
the boards of Fortune 500 companies 
increased from 22% in 1987 to 84% in 
2011.4 Although the Sarbanes-Oxley 
Act applies only to public companies, 
many of its key provisions have been 
adopted voluntarily by nonprofit 
hospitals and health systems. Several 
authorities, including the Internal 
Revenue Service, have called for a 
majority of board members in nonprofit 
organizations to be independent.
For the purpose of this study, the 
term “independent board member” 
was defined as persons who are “not a 
member of a sponsoring body such as a 
religious congregation, not a full- or part-
time system employee, and not directly 
affiliated with the system in any way 
except serving as a voting board member.” 
Table 1 shows that, in total, 60% of the 
members of the 14 system boards in this 
study population meet these criteria. 
However, 82% of board members in the 5 
secular health systems meet the criteria for 
independence — virtually identical to the 
current composition of America’s public 
companies — while only 49% of faith-
based system board members meet those 
criteria. Clearly, the composition of most 
faith-based system boards still includes 
a substantial proportion of persons 
who are affiliated with the previous or 
current religious sponsors. The range of 
independent member composition varies 
from 18% for 1 faith-based system to 
100% for 1 secular system, the single 
system in which the CEO is not a voting 
member of the board. 
Diversity. In the health care field 
and other sectors, there is agreement 
that governing boards must include 
persons with a strong blend of pertinent 
experience and skills in order to perform 
their fiduciary duties effectively. It 
is increasingly recognized that the 
boards of nonprofit organizations also 
should include members with diverse 
backgrounds and perspectives.
Table 2 shows the proportion of 
nonwhites serving on the boards of 
the 14 large systems in this study 
population. In total, 17% of the systems’ 
board members are nonwhite; the 
proportion of those serving on faith-
based vs. secular boards is virtually 
identical. This is somewhat higher 
than the comparable figure (10%) for 
hospitals that participated in a 2011 
survey conducted by the American 
Hospital Association (AHA).5 
Table 3 shows the gender mix of the 
14 systems’ boards. Although there is 
some variation from board to board, the 
overall proportion of women serving on 
the boards of the 9 faith-based systems 
(40%) is significantly higher than the 
corresponding figure for the secular 
systems (21%). Collectively, hospitals 
and health systems that participated in 
a nationwide survey by the Governance 
Institute in 2011 reported that 26% of 
their board members were women.6 
As compared to America’s Fortune 
500 companies, the boards of these 
14 large, nonprofit health systems are 
more diverse, both in racial and gender 
composition. In 2011, only 14% of 
Fortune 500 board members were 
nonwhite and only 16% were women.4 
It appears that our nation’s largest 
nonprofit health systems are responding 
to what is, on balance, a compelling case 
for diversity in board composition.
Clinical Engagement. The National 
Quality Forum and other prominent 
health care organizations have urged 
hospital and health system boards to 
engage clinical leaders in developing 
strategies to improve patient care quality 
and safety. Involving highly qualified 
physicians who are committed to 
the organization’s mission has become 
a standard governance practice. The 
findings of several national studies in 
Table 2. Racial Composition of Large System Boards 
Board Composition 
in Faith-Based 
Systems (n = 179)
Board Composition 
in Secular Systems  
(n = 95)   
Board Composition 
in All Systems 
(n = 274)
Nonwhite 
Members
17% 18% 17%
White Members 83% 82% 83%
N/S* 100% 100% 100%
*The observed differences were not statistically significant
Table 1. Independent vs. Non-Independent Board Members
Board Composition 
in Faith-Based 
Systems (n = 179)
Board Composition 
in Secular Systems  
(n = 95)   
Board Composition 
in All Systems 
(n = 274)
Independent 49% 82% 60%
Non-Independent 51% 18% 40% 
P < .01* 100% 100% 100%
 *The chi-square test demonstrates significantly different proportions of independent board members in faith-based systems.
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recent years show physicians generally 
constitute approximately 20% of hospital 
and health system board membership. 
In contrast, engaging nursing 
profession leaders in the governance of 
health care organizations traditionally 
has not been a common practice. 
Studies completed in 2005 and 2009 
found that nurses comprised only 
about 2% of nonprofit hospital and 
community health system boards.7,8 
Recognizing the vital role of nursing 
in determining the quality and cost of 
care, a growing number of respected 
organizations including the Robert 
Wood Johnson Foundation have urged 
hospital and health system officials to 
consider the appointment of highly 
qualified nurse leaders to their boards. 
Table 4 shows that, in combination, 
14% of the study populations’ board 
members are physicians and 6% are 
nurses. Physicians are somewhat more 
prominent on the boards of secular 
systems (18%) as compared to faith-
based systems (11%); nurses comprise 
a larger proportion of the faith-based 
system boards (9%) than the secular 
system boards (2%). In both groups, 
clinicians collectively constitute 20% of 
the systems’ voting board membership.
The finding that 6% of large system 
board members are nurses is exactly 
consistent with the results of the AHA’s 
2011 survey of American hospitals.5 
These findings appear to represent a 
shift in the direction that Hassmiller 
and Combes, and others believe is “…
long overdue.” 9 
Conclusion 
With respect to board size and 
composition, the boards of these large 
systems are somewhat more consistent 
with current benchmarks of effective 
governance than the country’s hospitals 
and health systems as a whole. The 
board leaders and CEOs of these 
systems are encouraged to continue 
their efforts to identify opportunities 
to improve their governance model and 
performance.
Lawrence Prybil, PhD, LFACHE, is 
Norton Professor in Healthcare Leadership 
and Associate Dean, College of Public 
Health, University of Kentucky. He can be 
contacted at Lpr224@uky.edu
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Table 3. Gender Composition of Large System Boards
Board Composition 
in Faith-Based 
Systems (n = 179)
Board Composition 
in Secular Systems  
(n = 95)   
Board Composition 
in All Systems 
(n = 274)
Women 40% 21% 33%
Men 60% 79% 67%
P < .01* 100% 100% 100%
*The chi-square test demonstrates significantly different proportions of women board members in faith-based vs. secular systems.
Table 4. Clinician Composition of Large System Boards
Board Composition 
in Faith-Based 
Systems (n = 179)
Board Composition 
in Secular Systems  
(n = 95)   
Board Composition 
in All Systems 
(n = 274)
Nurses 9% 2% 6%
Physicians 11% 18% 14%
Other 80% 80% 80%
P < .05* 100% 100% 100%
*The chi-square test demonstrates significantly different proportions of nurses in the board compositions of faith-based vs. 
secular systems.
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